Refludan European Union - English - EMA (European Medicines Agency)

refludan

celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antithrombotic agents - anticoagulation in adult patients with heparin-induced thrombocytopenia type ii and thromboembolic disease mandating parenteral antithrombotic therapy.the diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.

REFLUDAN POWDER FOR SOLUTION Canada - English - Health Canada

refludan powder for solution

bayer inc - lepirudin - powder for solution - 50mg - lepirudin 50mg - direct thrombin inhibitors

Refludan New Zealand - English - Medsafe (Medicines Safety Authority)

refludan

sanofi-aventis new zealand limited - lepirudin 50mg - powder for injection - 50 mg - active: lepirudin 50mg excipient: mannitol sodium hydroxide

BIVALIRUDIN CIPLA 250 Milligram Pdr/Conc/Soln/Inj/Inf Ireland - English - HPRA (Health Products Regulatory Authority)

bivalirudin cipla 250 milligram pdr/conc/soln/inj/inf

cipla (eu) limited - bivalirudin - pdr/conc/soln/inj/inf - 250 milligram - direct thrombin inhibitors

Angiox European Union - English - EMA (European Medicines Agency)

angiox

the medicines company uk ltd - bivalirudin - acute coronary syndrome - antithrombotic agents - angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (pci), including patients with st-segment-elevation myocardial infarction (stemi) undergoing primary pci.angiox is also indicated for the treatment of adult patients with unstable angina / non-st-segment-elevation myocardial infarction (ua / nstemi) planned for urgent or early intervention.angiox should be administered with aspirin and clopidogrel.